NASDAQ: LNSRLensar Inc Stock
$14.05+0.00 (+0%)
Updated Apr 30, 2025
LNSR Price
$14.05
Fair Value Price
N/A
Market Cap
$165.64M
52 Week Low
$3.02
52 Week High
$17.31
P/E
-5.15x
P/B
34.07x
P/S
1.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$53.49M
Earnings
-$31.40M
Gross Margin
48.3%
Operating Margin
-58.7%
Profit Margin
-58.7%
Debt to Equity
9.8
Operating Cash Flow
-$2M
Beta
0.45
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LNSR Overview
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LNSR's potential to beat the market
- LNSR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LNSR
RankedUnranked of 108
RankedUnranked of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.31 | A | |
| $23.03 | A | |
| $14.12 | A |
Be the first to know about important LNSR news, forecast changes, insider trades & much more!
LNSR News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LNSR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LNSR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LNSR is poor value based on its book value relative to its share price (34.07x), compared to the US Medical Devices industry average (3.94x)
P/B vs Industry Valuation
LNSR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LNSR due diligence checks available for Premium users.
Valuation
LNSR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.15x
Industry
37.39x
Market
29.18x
LNSR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
34.07x
Industry
3.94x
LNSR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LNSR's financial health
Profit margin
Revenue
$16.7M
Net Income
-$18.7M
Profit Margin
-111.8%
LNSR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LNSR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$66.3M
Liabilities
$47.7M
Debt to equity
9.8
LNSR's short-term assets ($41.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LNSR's short-term assets ($41.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LNSR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LNSR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.7M
Investing
$2.0M
Financing
$172.0k
LNSR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LNSR vs Medical Device Stocks
Lensar Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.